Novan (NASDAQ:NOVN) issued its quarterly earnings results on Tuesday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.37), Bloomberg Earnings reports. Novan had a negative return on equity of 2,068.56% and a negative net margin of 225.10%.

NASDAQ NOVN traded down $0.11 on Wednesday, reaching $2.37. 1,700 shares of the stock traded hands, compared to its average volume of 228,305. The stock’s fifty day simple moving average is $2.69. The company has a market cap of $64.65 million, a P/E ratio of -2.12 and a beta of 1.84. Novan has a 12 month low of $0.65 and a 12 month high of $3.24.

In other Novan news, major shareholder Life Sciences Holdings L. Malin sold 25,000 shares of Novan stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $2.71, for a total transaction of $67,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paula B. Stafford bought 80,693 shares of the firm’s stock in a transaction on Monday, May 20th. The shares were purchased at an average cost of $1.92 per share, with a total value of $154,930.56. Following the completion of the transaction, the insider now owns 693 shares in the company, valued at $1,330.56. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 229,786 shares of company stock valued at $426,138. 5.36% of the stock is currently owned by corporate insiders.

A number of equities research analysts recently issued reports on NOVN shares. ValuEngine raised Novan from a “sell” rating to a “hold” rating in a research note on Thursday, May 23rd. Zacks Investment Research lowered Novan from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th.

Novan Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: What is a front-end load?

Earnings History for Novan (NASDAQ:NOVN)

Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with's FREE daily email newsletter.